Oppenheimer Gives a Hold Rating to BioMarin Pharmaceutical (BMRN)
Oppenheimer analyst Leland Gershell assigned a Hold rating to BioMarin Pharmaceutical (BMRN) today and set a price target of $116.00. The company’s shares closed last Wednesday at $120.33.
According to TipRanks.com, Gershell is a 5-star analyst with an average return of 18.7% and a 51.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, Corbus Pharmaceuticals, and Anchiano Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioMarin Pharmaceutical with a $129.84 average price target.
See today’s analyst top recommended stocks >>
Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $502 million and net profit of $81.38 million. In comparison, last year the company earned revenue of $401 million and had a GAAP net loss of $56.47 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.